Genesis Biologics, Inc.

Genesis Biologics is a medical device manufacturer and distributor specializing in orthobiologics, allograft tissue, and soft-tissue repair technologies. The company's core product is the Adaptive Autologous Processing System (AAPS), a patented platform for point-of-care platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) processing. The AAPS consists of the proprietary Dial-In Syringe and Boost 2+ Flex Digital Centrifuge, enabling clinicians to produce patient-specific PRP concentrations with precise dosage control. The system achieves mean platelet capture rates of 78% with up to 98% capability, supporting multi-level preparations from 2x to 10x baseline concentrations, with options for both leukocyte-rich and leukocyte-poor formulations. Spin cycles are rapid (2–5 minutes), designed for clinic and operating room use. Genesis also manufactures HD PRP (High-Definition Platelet Rich Plasma) concentrate, a pre-filled, FDA-cleared Class II medical device available in 15 mL and 30 mL formats with proprietary gel components that reduce red blood cells by 99% and white blood cells by 92%. The company's allograft portfolio includes conventional bone products (dowels, shafts, whole bones), demineralized bone matrix (DBM) putty, chips, and fibers, as well as sports medicine soft-tissue allografts. All allograft tissue is sourced from facilities maintaining industry-standard quality and safety protocols. Genesis serves orthopedic surgeons, sports medicine practitioners, and regenerative medicine clinics with both autologous biologic processing systems and ready-to-use allograft solutions.